Monitor for any revenue guidance or sales updates from Catheter Precision in future Flyte Aviation filings, as this study could drive adoption of LockeT but the financial materiality to the holding company is not quantified.
Price Chart
Executive Summary
Flyte Aviation subsidiary Catheter Precision announced a peer-reviewed study showing its LockeT suture retention device had fewer complications (1.2% vs 9.3%) and zero device failures compared to Abbott's Perclose VCD in a 172-patient trial. The positive clinical data supports LockeT's competitive positioning in the vascular closure market, but the filing is a press release from a holding company whose primary business is private aviation, making the direct financial impact on Flyte Aviation unclear.
Key Facts
- LockeT reduced cumulative access-site complications to 1.2% vs 9.3% for Perclose (Abbott).
- LockeT achieved 0.0% device failure rate vs 4.7% for Perclose.
- Study published in The Journal of Interventional Cardiology (JICE), a peer-reviewed journal.
- LockeT is a Class 1 FDA-registered device with CE Mark approval, selling in US, Europe, and South America.
- Catheter Precision is a wholly owned subsidiary of Flyte Aviation, Inc. (NYSE American: VJET).
Financial Impact
No revenue, sales, or financial figures provided for LockeT or Catheter Precision.
Risk Factors
- Flyte Aviation's primary business is private aviation; the medical device subsidiary may be a small portion of overall operations.
- No financial data (revenue, market size, or adoption rates) was provided to quantify the commercial impact.
- Competitive response from Abbott or other VCD manufacturers could limit market share gains.
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3386951 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Press Release | $0.6900 | awaiting T+1 | — | $0.6500 (−5.80%) |
Oct 22, 2026 4d ago | Press Release | $0.7080 $0.6455 | ▼ −8.83% | ▼ −9.54% | $0.6500 (−8.19%) |
Oct 20, 2026 6d ago | Press Release | $0.7151 $0.7013 | ▼ −1.93% | ▼ −0.75% | $0.6500 (−9.10%) |
Oct 14, 2026 12d ago | 8-K | $0.9770 $0.8400 | ▼ −14.02% | ▼ −12.92% | $0.6500 (−33.47%) |
Oct 13, 2026 13d ago | 8-K | $0.8790 $0.9770 | ▲ +11.15% | ▲ +10.86% | $0.6500 (−26.05%) |
Oct 5, 2026 21d ago | 8-K | $1.03 $0.9300 | ▼ −9.71% | ▼ −9.47% | $0.6500 (−36.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers